Compare RMBS & MEDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RMBS | MEDP |
|---|---|---|
| Founded | 1990 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.6B | 13.0B |
| IPO Year | 1997 | 2016 |
| Metric | RMBS | MEDP |
|---|---|---|
| Price | $122.96 | $520.56 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 7 | 12 |
| Target Price | $137.00 | ★ $473.17 |
| AVG Volume (30 Days) | ★ 2.7M | 280.5K |
| Earning Date | 04-27-2026 | 04-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 27.88 | 20.98 |
| EPS | 0.55 | ★ 4.28 |
| Revenue | ★ $707,630,000.00 | N/A |
| Revenue This Year | $16.01 | $13.19 |
| Revenue Next Year | $16.23 | $7.75 |
| P/E Ratio | $223.93 | ★ $121.60 |
| Revenue Growth | ★ 27.13 | N/A |
| 52 Week Low | $61.16 | $306.70 |
| 52 Week High | $174.10 | $628.92 |
| Indicator | RMBS | MEDP |
|---|---|---|
| Relative Strength Index (RSI) | 40.83 | 75.58 |
| Support Level | $87.66 | $489.09 |
| Resistance Level | $133.45 | $539.06 |
| Average True Range (ATR) | 12.58 | 17.53 |
| MACD | -3.63 | 5.56 |
| Stochastic Oscillator | 6.80 | 86.91 |
Rambus Inc is a semiconductor company providing chips and silicon IP for data-intensive computing systems, focusing on data center and artificial intelligence (AI) infrastructure. The company is at the forefront of enabling the next era of AI-driven computing, addressing challenges of signal and power integrity at increasingly extreme data rates across the data center, edge, and client markets. It offers high-performance memory subsystems, with a balanced and diverse portfolio of products, IP, and patents that maximize performance and security in computationally intensive systems. The company operates in South Korea, Singapore, the United States, and other countries, with the majority of its revenue coming from South Korea.
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.